Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0729 USD | +5.65% | -8.76% | -51.85% |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.85% | 16.9M | - | - | |
+2.56% | 108B | B+ | ||
+10.02% | 104B | B+ | ||
+7.74% | 23.66B | B | ||
-11.91% | 22.1B | B+ | ||
-3.29% | 19.71B | A- | ||
-35.98% | 18.2B | A- | ||
-14.02% | 16.19B | B | ||
+4.61% | 13.72B | C+ | ||
+35.05% | 12.22B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Jaguar Health, Inc. - Nasdaq
- Ratings Jaguar Health, Inc.